78 related articles for article (PubMed ID: 21544439)
1. Relationship of cellular energy parameters to cytotoxicity for AG-17, lonidamine and cyclocreatine in four human tumor cell lines.
Ara G; Teicher B
Int J Oncol; 1996 May; 8(5):865-73. PubMed ID: 21544439
[TBL] [Abstract][Full Text] [Related]
2. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
3. Cyclocreatine in cancer chemotherapy.
Teicher BA; Menon K; Northey D; Liu J; Kufe DW; Kaddurah-Daouk R
Cancer Chemother Pharmacol; 1995; 35(5):411-6. PubMed ID: 7850923
[TBL] [Abstract][Full Text] [Related]
4. Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase.
Mulvaney PT; Stracke ML; Nam SW; Woodhouse E; O'Keefe M; Clair T; Liotta LA; Khaddurah-Daouk R; Schiffmann E
Int J Cancer; 1998 Sep; 78(1):46-52. PubMed ID: 9724093
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
Brooks SE; Korbut TT; Dupuis NP; Holden SA; Teicher BA
Cancer Chemother Pharmacol; 1995; 36(5):431-8. PubMed ID: 7634385
[TBL] [Abstract][Full Text] [Related]
6. Specific targeting of tumor cells by the creatine analog cyclocreatine.
Martin K; Winslow E; Okeefe M; Khandekar V; Hamlin A; Lillie J; Kaddurahdaouk R
Int J Oncol; 1996 Nov; 9(5):993-9. PubMed ID: 21541606
[TBL] [Abstract][Full Text] [Related]
7. Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: effect on cellular sensitivity to cytotoxic agents.
Townsend AJ; Tu CP; Cowan KH
Mol Pharmacol; 1992 Feb; 41(2):230-6. PubMed ID: 1538704
[TBL] [Abstract][Full Text] [Related]
8. [Lonidamine induces apoptosis via endoplasmic reticulum stress response and down-regulating cIAP expression in human breast carcinoma MCF-7 cells].
Shao F; Wang L; Chu X
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jun; 35(6):883-7. PubMed ID: 26111690
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
Ning SC; Hahn GM
Cancer Res; 1990 Dec; 50(24):7867-70. PubMed ID: 2253227
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of lonidamine and tamoxifen in human breast-cancer cell-lines.
Gornati D; Zaffaroni N; Orlandi L; Difronzo G; Silvestrini R
Int J Oncol; 1995 May; 6(5):993-6. PubMed ID: 21556629
[TBL] [Abstract][Full Text] [Related]
11. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells.
Fanciulli M; Valentini A; Bruno T; Citro G; Zupi G; Floridi A
Oncol Res; 1996; 8(3):111-20. PubMed ID: 8823807
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells.
Martin KJ; Chen SF; Clark GM; Degen D; Wajima M; Von Hoff DD; Kaddurah-Daouk R
J Natl Cancer Inst; 1994 Apr; 86(8):608-13. PubMed ID: 8145276
[TBL] [Abstract][Full Text] [Related]
13. Morphological effects of lonidamine on two human-tumor cell culture lines.
Szekely JG; Lobreau AU; Delaney S; Raaphorst GP; Feeley M
Scanning Microsc; 1989 Jun; 3(2):681-91; discussion 691-3. PubMed ID: 2814409
[TBL] [Abstract][Full Text] [Related]
14. Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis.
Bergnes G; Yuan W; Khandekar VS; O'Keefe MM; Martin KJ; Teicher BA; Kaddurah-Daouk R
Oncol Res; 1996; 8(3):121-30. PubMed ID: 8823808
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.
Hoosein NM; Martin KJ; Abdul M; Logothetis CJ; Kaddurah-Daouk R
Anticancer Res; 1995; 15(4):1339-42. PubMed ID: 7654018
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle studies of cyclocreatine, a new anticancer agent.
Martin KJ; Winslow ER; Kaddurah-Daouk R
Cancer Res; 1994 Oct; 54(19):5160-5. PubMed ID: 7923134
[TBL] [Abstract][Full Text] [Related]
17. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine.
Kiura K; Ohnoshi T; Ueoka H; Takigawa N; Tabata M; Segawa Y; Shibayama T; Kimura I
Anticancer Drug Des; 1992 Dec; 7(6):463-70. PubMed ID: 1337430
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent modulation of idarubicin cytotoxicity by lonidamine in human lymphoma cell lines.
Zaffaroni N; Villa R; Gornati D; Folini M; Silvestrini R
Int J Oncol; 1997 Oct; 11(4):675-9. PubMed ID: 21528260
[TBL] [Abstract][Full Text] [Related]
19. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.
Floridi A; Paggi MG; D'Atri S; De Martino C; Marcante ML; Silvestrini B; Caputo A
Cancer Res; 1981 Nov; 41(11 Pt 1):4661-6. PubMed ID: 7306982
[TBL] [Abstract][Full Text] [Related]
20. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents.
Lu K; Shih C; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(4):293-304. PubMed ID: 11052627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
